[go: up one dir, main page]

TR200002475T2 - Fumar asidi türevlerinin transplantasyon hekimliğinde kullanılması. - Google Patents

Fumar asidi türevlerinin transplantasyon hekimliğinde kullanılması.

Info

Publication number
TR200002475T2
TR200002475T2 TR2000/02475T TR200002475T TR200002475T2 TR 200002475 T2 TR200002475 T2 TR 200002475T2 TR 2000/02475 T TR2000/02475 T TR 2000/02475T TR 200002475 T TR200002475 T TR 200002475T TR 200002475 T2 TR200002475 T2 TR 200002475T2
Authority
TR
Turkey
Prior art keywords
fumar acid
acid derivatives
transplantation medicine
medicine
combination
Prior art date
Application number
TR2000/02475T
Other languages
English (en)
Inventor
Rajendra Joshi Kumar
Strebel Hans-Peter
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of TR200002475T2 publication Critical patent/TR200002475T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bulus, belli fumar asidi monoalkil esterlerinin tuzlar veya serbest asitler olarak, sadece bir dialkil fumarat ile kombine edilmek suretiyle, transplantasyon hekimligi alaninda kullanilan tibbi eczalarin imalatinda, özellikle Host -versus- Graft reaksiyonlarinin tedavisinde, hafifletilmesinde veya bastirilmasinda kullanilmasi ile ilgilidir. Fumar asidi monoalkil esterleri bu amaçla transplantasyon hekimliginin alisilagelmis preparatlari ve özellikle Siklosporinler olmak üzere Immünosüpresifler ile kombine edilerek kullanilabilir.
TR2000/02475T 1998-08-31 1999-08-20 Fumar asidi türevlerinin transplantasyon hekimliğinde kullanılması. TR200002475T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19839566A DE19839566C2 (de) 1998-08-31 1998-08-31 Verwendung von Fumarsäurederivaten in der Transplantationsmedizin

Publications (1)

Publication Number Publication Date
TR200002475T2 true TR200002475T2 (tr) 2001-03-21

Family

ID=7879272

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02475T TR200002475T2 (tr) 1998-08-31 1999-08-20 Fumar asidi türevlerinin transplantasyon hekimliğinde kullanılması.

Country Status (25)

Country Link
US (1) US6359003B1 (tr)
EP (1) EP1107749B1 (tr)
JP (1) JP3553883B2 (tr)
CN (1) CN1195511C (tr)
AT (1) ATE241353T1 (tr)
AU (1) AU746958B2 (tr)
BG (1) BG64435B1 (tr)
BR (1) BR9908722A (tr)
CA (1) CA2322188C (tr)
DE (2) DE19839566C2 (tr)
DK (1) DK1107749T3 (tr)
EE (1) EE05025B1 (tr)
ES (1) ES2195609T3 (tr)
HK (1) HK1040623B (tr)
HU (1) HUP0101854A3 (tr)
IL (1) IL138110A0 (tr)
NO (1) NO20006462L (tr)
NZ (1) NZ506573A (tr)
PL (1) PL198211B1 (tr)
PT (1) PT1107749E (tr)
RS (1) RS49780B (tr)
RU (1) RU2210364C2 (tr)
SK (1) SK286352B6 (tr)
TR (1) TR200002475T2 (tr)
WO (1) WO2000012072A2 (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6342294B1 (en) 1999-08-12 2002-01-29 Bruce G. Ruefer Composite PTFE article and method of manufacture
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
CZ304198B6 (cs) * 2001-01-12 2013-12-27 Fumapharm Ag Amidy kyseliny fumarové
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
AU2003236156A1 (en) * 2003-04-24 2005-01-04 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
ES2582942T3 (es) * 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
PL2137537T3 (pl) 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
EP2379063B2 (en) 2009-01-09 2021-02-24 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EA201391638A1 (ru) 2011-06-08 2014-05-30 Байоджен Айдек Ма Инк. Способ получения высокочистого и кристаллического диметилфумарата
CN103826624A (zh) * 2011-08-30 2014-05-28 富山化学工业株式会社 类风湿性关节炎等自身免疫疾病的处置的改善方法
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
EP2812319A1 (en) 2012-02-07 2014-12-17 XenoPort, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
KR102105217B1 (ko) * 2012-02-07 2020-06-01 바이오젠 엠에이 인코포레이티드 다이메틸 푸마레이트를 함유하는 약학 조성물
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
EP2887933A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN103483194B (zh) * 2012-11-30 2016-03-09 杨寅柯 一种2-氟代富马酸酯(结构式i)及其制备方法及应用
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
JP6373353B2 (ja) 2013-03-14 2018-08-15 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのプロドラッグおよび種々の疾患の治療におけるその使用
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015127450A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
UA121323C2 (uk) 2015-02-08 2020-05-12 Алкермес Фарма Айрленд Лімітед Композиції на основі проліків монометилфумарату
EP3273951B1 (en) 2015-03-27 2020-07-29 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
CN106265621B (zh) * 2016-09-19 2019-05-17 苏州大学 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
EP1886677A1 (en) * 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn

Also Published As

Publication number Publication date
PT1107749E (pt) 2003-08-29
CA2322188A1 (en) 2000-03-09
EP1107749B1 (de) 2003-05-28
SK286352B6 (en) 2008-07-07
JP3553883B2 (ja) 2004-08-11
NO20006462D0 (no) 2000-12-18
EE200000654A (et) 2002-04-15
AU746958B2 (en) 2002-05-09
HK1040623B (zh) 2005-08-19
NZ506573A (en) 2002-10-25
IL138110A0 (en) 2001-10-31
HK1040623A1 (en) 2002-06-21
US6359003B1 (en) 2002-03-19
RU2210364C2 (ru) 2003-08-20
AU5737899A (en) 2000-03-21
HUP0101854A2 (hu) 2001-11-28
RS49780B (sr) 2008-06-05
BG104679A (en) 2001-02-28
WO2000012072A2 (de) 2000-03-09
SK2572001A3 (en) 2002-05-09
EE05025B1 (et) 2008-06-16
NO20006462L (no) 2001-04-30
CN1316901A (zh) 2001-10-10
CA2322188C (en) 2004-03-09
DE59905763D1 (de) 2003-07-03
DE19839566C2 (de) 2002-01-17
JP2002525276A (ja) 2002-08-13
ES2195609T3 (es) 2003-12-01
BG64435B1 (en) 2005-02-28
DE19839566A1 (de) 2000-03-09
ATE241353T1 (de) 2003-06-15
PL347359A1 (en) 2002-04-08
HUP0101854A3 (en) 2003-04-28
YU58800A (sh) 2002-03-18
WO2000012072A3 (de) 2000-05-04
PL198211B1 (pl) 2008-06-30
BR9908722A (pt) 2001-10-16
DK1107749T3 (da) 2003-08-18
EP1107749A2 (de) 2001-06-20
CN1195511C (zh) 2005-04-06

Similar Documents

Publication Publication Date Title
TR200002475T2 (tr) Fumar asidi türevlerinin transplantasyon hekimliğinde kullanılması.
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
ECSP034922A (es) Pirrolopirimidinas
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
EP0934065A4 (en) PHARMACEUTICAL COMPOSITION
TR200000349T2 (tr) Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.
EP1180017B8 (en) Preparations with povidon iodine for wound treatment
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
TR200201654T2 (tr) Benzamidin türevleri.
ATE127344T1 (de) Aldosereduktasehemmer enthaltende zubereitungen zur behandlung von geschwüren.
DK1178960T3 (da) Vitamin D analoger og deres farmaceutiske anvendelse
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
TR200001133A2 (tr) Serabral asetilkolin salgılamasını zenginleştirmek için madde
Tangjaturonrusamee et al. Methylene Blue: Its Efficacy and Safety as a Storage Solution in Hair Transplantation